About
Callisto Pharmaceuticals is a public biotechnology company that develops novel therapeutics to treat gastrointestinal diseases and cancer. We source our drug candidates from breakthrough science, both internal and external. Our management has deep experience in drug development from both large pharmaceutical companies and smaller biotechnology companies. We pride ourselves on discovering and seeking out new or overlooked therapeutic approaches with the potential to improve the lives of large number of patients.
We currently have 3 drugs in development:
- SP-304, also called Guanilib, is our oral guanylate cyclase C (GC-C) receptor agonist. It is in late pre-clinical development for chronic constipation and constipation-predominant irritable bowel syndrome. Guanilib is one of only two drugs in a new class of highly efficacious compounds for these very large and underserved markets.
- Atiprimod is an orally available small molecule drug that displays a multiplicity of anti-cancer mechanistic activities. The drug is presently in Phase II development for advanced carcinoid cancer and has potential in several other cancers, including liver and colon as well as mantle cell lymphoma.
- L-Annamycin is a liposome nanoparticle formulation of a second generation anthracycline. It has been developed to address shortcomings with the current generation anthracycline drugs to treat relapsed acute leukemia patients. L-Annamycin has the potential to work against anthracycline-resistant tumors, is expected to have reduced cardiotoxicity. The compound is currently in Phase I/IIa trials for adult and children with relapsed or refractory acute leukemia.
Callisto’s main office is located in Manhattan, New York, NY. Our laboratories are in Doylestown PA. The company is listed on the American Stock Exchange under the symbol KAL as well as on the Frankfurt Stock Exchange under the symbol CA4.
Download our Company Profile
